[go: up one dir, main page]

MA28082A1 - Administration de ligands tlr7 et de leurs prodrogues pour traiter l'infection au virus de l'hepatite c - Google Patents

Administration de ligands tlr7 et de leurs prodrogues pour traiter l'infection au virus de l'hepatite c

Info

Publication number
MA28082A1
MA28082A1 MA28909A MA28909A MA28082A1 MA 28082 A1 MA28082 A1 MA 28082A1 MA 28909 A MA28909 A MA 28909A MA 28909 A MA28909 A MA 28909A MA 28082 A1 MA28082 A1 MA 28082A1
Authority
MA
Morocco
Prior art keywords
tlr7
virus infection
administration
products
prodrugs
Prior art date
Application number
MA28909A
Other languages
English (en)
Inventor
Devron R Averett
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of MA28082A1 publication Critical patent/MA28082A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ABSTRAIT DE L'INVENTION [00330] La présente invention concerne des méthodes pour le traitement ou la prévention des infections au virus de l'hépatite C chez les mammifères en utilisant un ligand récepteur (TLR7) de type Toll et les prodrogues de ce dernier. Particulièrement, la présente invention concerne des méthodes pour l'administration par voie orale d'une quantité thérapeutiquement efficace d'une ou plusieurs prodrogues des ligands TLR7 pour le traitement ou la prévention de l'infection au virus de l'hépatite C. L'administration par voie orale de ces ligands et prodrogues TLR7 immimomodulateurs à un mammifère fournit des quantités thérapeutiquement efficace et des effets secondaires indésirables réduits.
MA28909A 2003-09-05 2006-04-03 Administration de ligands tlr7 et de leurs prodrogues pour traiter l'infection au virus de l'hepatite c MA28082A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50033903P 2003-09-05 2003-09-05
US51899603P 2003-11-10 2003-11-10
US51899703P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
MA28082A1 true MA28082A1 (fr) 2006-08-01

Family

ID=34317460

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28909A MA28082A1 (fr) 2003-09-05 2006-04-03 Administration de ligands tlr7 et de leurs prodrogues pour traiter l'infection au virus de l'hepatite c

Country Status (25)

Country Link
US (4) US7576068B2 (fr)
EP (1) EP1667694B1 (fr)
JP (1) JP2007504232A (fr)
KR (1) KR20060096415A (fr)
AP (1) AP2006003542A0 (fr)
AT (1) ATE465742T1 (fr)
AU (1) AU2004271972B2 (fr)
BR (1) BRPI0414045A (fr)
CA (1) CA2537450C (fr)
CR (1) CR8273A (fr)
DE (1) DE602004026891D1 (fr)
EA (1) EA200600540A1 (fr)
EC (1) ECSP066465A (fr)
ES (1) ES2342069T4 (fr)
GE (1) GEP20084545B (fr)
IL (1) IL173890A (fr)
MA (1) MA28082A1 (fr)
MX (1) MXPA06002309A (fr)
NO (1) NO20061183L (fr)
NZ (1) NZ545536A (fr)
OA (1) OA13310A (fr)
SG (1) SG146637A1 (fr)
TN (1) TNSN06076A1 (fr)
TW (1) TWI347189B (fr)
WO (1) WO2005025583A2 (fr)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
JP2008531580A (ja) * 2000-12-08 2008-08-14 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾因子の標的化送達のための組成物および方法
US20030199466A1 (en) * 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
WO2003103584A2 (fr) 2002-06-07 2003-12-18 3M Innovative Properties Company Imidazopyridines a substitution ether
WO2004029054A1 (fr) 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Company, Limited Nouveau compose d'adenine et son application
JP2006515277A (ja) * 2002-10-29 2006-05-25 コーリー ファーマシューティカル グループ， リミテッド Ｃ型肝炎ウィルス感染の処置および予防に関する方法および製品
AU2003301052A1 (en) 2002-12-20 2004-07-22 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1617845A4 (fr) * 2003-04-28 2006-09-20 3M Innovative Properties Co Compositions et methodes d'induction de recepteurs opoides
TW200510412A (en) * 2003-08-12 2005-03-16 3M Innovative Properties Co Oxime substituted imidazo-containing compounds
EP2939693A1 (fr) * 2003-08-14 2015-11-04 3M Innovative Properties Company Modificateurs de réponse immunitaire modifiée par un lipide
JP2007503268A (ja) * 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
AR045529A1 (es) 2003-08-27 2005-11-02 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi
CA2537763A1 (fr) * 2003-09-05 2005-03-17 3M Innovative Properties Company Traitement pour le lymphome a cellules b cd5<sp>+</sp>
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
WO2005032484A2 (fr) 2003-10-03 2005-04-14 3M Innovative Properties Company Imidazoquinolines a substitution alcoxy
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
KR101494056B1 (ko) 2003-10-03 2015-02-16 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
JP2007511527A (ja) * 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ環化合物
EP1682544A4 (fr) 2003-11-14 2009-05-06 3M Innovative Properties Co Composes d'un anneau d'imidazo substitue par hydroxylamine
AU2004293078B2 (en) * 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
JP2007512349A (ja) * 2003-11-25 2007-05-17 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミンおよびオキシム置換した、イミダゾキノリン、イミダゾピリジン、およびイミダゾナフチリジン
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
EP1694674A4 (fr) * 2003-12-04 2010-07-07 3M Innovative Properties Co Ethers cycliques imidazo substitues au sulfone
US8802853B2 (en) * 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US7888349B2 (en) * 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
EP1699788A2 (fr) * 2003-12-30 2006-09-13 3M Innovative Properties Company Sulfonamides d'imidazoquinolinyle, d'imidazopyridinyle et d'imidazonaphtyridinyle
EP1730143A2 (fr) * 2004-03-24 2006-12-13 3M Innovative Properties Company Imidazopyridines, imidazoquinolines, et imidazonaphthyridines a substitution amide
TWI392678B (zh) 2004-03-26 2013-04-11 Dainippon Sumitomo Pharma Co ９-取代-８-氧基腺嘌呤化合物
BRPI0510430A (pt) * 2004-04-28 2007-10-30 3M Innovative Properties Co composições e métodos para vacinação mucosal
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (fr) * 2004-06-14 2005-12-29 3M Innovative Properties Company Imidazopyridines, imidazoquinolines et imidazonaphthyridines a substitution uree
US8017779B2 (en) * 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP5128940B2 (ja) * 2004-06-18 2013-01-23 スリーエム イノベイティブ プロパティズ カンパニー 置換イミダゾキノリン、イミダゾピリジン、およびイミダゾナフチリジン
US7897609B2 (en) * 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006065280A2 (fr) * 2004-06-18 2006-06-22 3M Innovative Properties Company Composes a noyau imidazo a substitutif d'isoxazole, de dihydroisoxazole et d'oxadiazole
EP1786450A4 (fr) * 2004-08-27 2009-11-11 3M Innovative Properties Co Compositions immunostimulatrices contre le vih
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
ATE555786T1 (de) * 2004-09-02 2012-05-15 3M Innovative Properties Co 1-alkoxy 1h-imidazo-ringsysteme und verfahren
CA2578975A1 (fr) 2004-09-02 2006-03-16 3M Innovative Properties Company Systemes cycliques de 2-amino 1h imidazo et procedes correspondants
EP1804583A4 (fr) * 2004-10-08 2009-05-20 3M Innovative Properties Co Adjuvant pour vaccin a adn
US20110070575A1 (en) * 2004-12-08 2011-03-24 Coley Pharmaceutical Group, Inc. Immunomodulatory Compositions, Combinations and Methods
AR052447A1 (es) * 2004-12-30 2007-03-21 3M Innovative Properties Co Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
WO2006071997A2 (fr) * 2004-12-30 2006-07-06 3M Innovative Properties Company Traitement de metastases cutanees
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
WO2006083440A2 (fr) 2004-12-30 2006-08-10 3M Innovative Properties Company Composes chiraux [1,2]imidazo[4,5-c] substitues a noyau fusionne
WO2006084251A2 (fr) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Formulations des gel aqueux contenant des modificateurs de reponse immunitaire
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006091568A2 (fr) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Imidazonaphthyridines a substitution hydroxyalkyle
AU2006216798A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1850849A2 (fr) 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Methode d'induction preferentielle de la biosynthese d'interferon
WO2006098852A2 (fr) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Imidazoquinolines a substitution hydroxyalkyle
JP2008533148A (ja) 2005-03-14 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー 光線性角化症の治療方法
CA2602590A1 (fr) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Composes cycliques 1-pyrazolo[3,4-c] substitues comme modulateurs de la biosynthese de cytokine destines au traitement d'infections virales et de maladies neoplastiques
WO2006107853A2 (fr) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines et analogues associes
CA2605808A1 (fr) * 2005-04-25 2006-11-02 3M Innovative Properties Company Compositions immunostimulantes
EA200702235A1 (ru) * 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
CA2615626A1 (fr) * 2005-07-18 2007-01-25 Novartis Ag Modele petit animal pour une replication hcv
JP2009504803A (ja) * 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
CN101300254A (zh) 2005-09-09 2008-11-05 科利制药集团公司 N－{2－[4－氨基－2－(乙氧基甲基)－1H－咪唑并[4,5－c]喹啉－1－基]－1,1－二甲基乙基}甲磺酰胺的酰胺和氨基甲酸酯衍生物和方法
CN101340931A (zh) * 2005-09-27 2009-01-07 科利制药公司 使用连接寡核苷酸调节tlr介导的免疫应答
KR20080083270A (ko) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
WO2007056527A2 (fr) * 2005-11-09 2007-05-18 Cheng Si Yuan (China-International) Hepatitis Research Foundation Methodes et agents diagnostiques et therapeutiques
TWI383987B (zh) 2005-11-21 2013-02-01 Anadys Pharmaceuticals Inc 製備５-胺基-３Ｈ-噻唑并〔４，５-ｄ〕嘧啶-２-酮之新穎方法
EP1987030B1 (fr) 2006-02-17 2011-11-09 Pfizer Limited Dérivés de 3-déazapurine en tant que modulateurs de tlr7
EP3085373A1 (fr) 2006-02-22 2016-10-26 3M Innovative Properties Company Conjugués de modificateur de réponse immunitaire
WO2007106854A2 (fr) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. 1h-imidazonaphthyridines hydroxy et alcoxy substituées, et procédés associés
EP2007789B1 (fr) 2006-04-11 2015-05-20 Novartis AG Inhibiteurs spirocycliques du VIH/du virus de l'hépatite C
JP2009534428A (ja) * 2006-04-25 2009-09-24 インターツェル・アクチェンゲゼルシャフト Ｈｃｖワクチン接種
EP2023722A4 (fr) * 2006-05-15 2012-01-18 Univ Kentucky Stimulation du récepteur de type toll (tlr) utile dans l'angiogenèse oculaire et la dégénérescence maculaire
AR061024A1 (es) * 2006-05-22 2008-07-30 Novartis Ag Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
EP2029597A4 (fr) * 2006-05-31 2011-11-23 Univ California Analogues de la purine
CN101516192B (zh) * 2006-06-22 2012-09-19 安那迪斯药品股份有限公司 5-氨基-3-(3'-脱氧-β-D-呋喃核糖基)-噻唑并[4,5-d]嘧啶-2,7-二酮的前药
JP2009542645A (ja) * 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
US7906506B2 (en) * 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
BRPI0714831A2 (pt) * 2006-07-18 2013-04-02 Anadys Pharmaceuticals Inc composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo
WO2008030511A2 (fr) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. 3, 4, 6, 7-tétrahydro-5h-1, 2a, 4a, 8-tétraazacyclopenta[cd]phénalènes substitués
BRPI0717741A2 (pt) * 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
ES2607901T3 (es) 2007-01-31 2017-04-04 Chongxi Yu Profármacos hidrosolubles cargados positivamente de 1H-imidazo[4,5-c]quinolin-4-aminas y compuestos relacionados con ratas de penetración de piel muy altas
DK2510946T3 (en) * 2007-02-07 2015-11-02 Univ California Conjugates of synthetic fluorescent agonists and their applications
WO2008101867A1 (fr) * 2007-02-19 2008-08-28 Smithkline Beecham Corporation Utilisation de dérivés de purine comme immunomodulateurs
JP5480637B2 (ja) * 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
ATE530549T1 (de) * 2007-03-19 2011-11-15 Astrazeneca Ab 9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-receptor (tlr7)
US8044056B2 (en) * 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
DK2155743T3 (da) * 2007-05-08 2012-11-05 Astrazeneca Ab Imidazoquinoliner med immunmodulerende egenskaber
US20110166092A1 (en) * 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
CA2713438A1 (fr) * 2008-02-07 2009-08-13 The Regents Of The University Of California Traitement des maladies de la vessie avec un activateur de tlr7
JP5519670B2 (ja) 2008-08-11 2014-06-11 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
MX2011001663A (es) 2008-08-11 2011-03-24 Glaxosmithkline Llc Derivados novedosos de adenina.
BRPI0921685A2 (pt) * 2008-10-31 2016-02-16 Moberg Derma Ab composição tópica compreendendo uma combinação de pelo menos dois agentes que melhoram a penetração.
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
NZ612380A (en) 2008-12-09 2015-01-30 Gilead Sciences Inc Modulators of toll-like receptors
HUE027823T2 (hu) 2008-12-09 2016-11-28 Coley Pharm Group Inc Immunstimuláló oligonukleotidok
WO2010091265A1 (fr) * 2009-02-05 2010-08-12 Yale University Composés et procédés destinés au traitement d'une encéphalite virale
WO2010088924A1 (fr) 2009-02-06 2010-08-12 Telormedix Sa Compositions pharmaceutiques comprenant des imidazoquinolines (amines) et des dérivés de celles-ci appropriés pour une administration locale
SG173617A1 (en) 2009-02-11 2011-09-29 Univ California Toll-like receptor modulators and treatment of diseases
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
WO2010133885A1 (fr) 2009-05-21 2010-11-25 Astrazeneca Ab Nouveaux dérivés pyrimidines et leur utilisation dans le traitement d'un cancer et autres maladies
EP2507237A1 (fr) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines agissant par l'intermédiaire des récepteurs de type toll (tlr)
JP2013519644A (ja) 2010-02-10 2013-05-30 グラクソスミスクライン エルエルシー プリン誘導体およびそれらの薬学的使用
WO2011101332A1 (fr) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions basées sur le domaine extracellulaire a de fibronectine pour le traitement d'un mélanome
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
CA2797315C (fr) 2010-04-30 2018-09-11 Telormedix Sa Analogues de medicaments phospholipidiques
SI2606047T1 (sl) 2010-08-17 2017-04-26 3M Innovative Properties Company Lipidirani sestavki spojine, ki modificira imunski odgovor, formulacije in postopki
KR20130120481A (ko) 2010-10-08 2013-11-04 노파르티스 아게 술파미드 ｎｓ3 억제제의 비타민 ｅ 제제
CN103370317B (zh) 2010-12-16 2015-10-07 阿斯利康(瑞典)有限公司 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
JP5978226B2 (ja) 2010-12-17 2016-08-24 大日本住友製薬株式会社 プリン誘導体
SI3590928T1 (sl) 2011-04-08 2021-10-29 Janssen Sciences Ireland Unlimited Co Derivati pirimidina za zdravljenje virusnih okužb
EP2717919B1 (fr) 2011-06-03 2016-08-03 3M Innovative Properties Company Lieurs hétérobifonctionnels comportant de segments de polyéthylène glycol et conjugués modificateurs de réponse immunitaire obtenus à partir de ceux-ci
JP6415979B2 (ja) 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
LT2734186T (lt) 2011-07-22 2018-12-10 Glaxosmithkline Llc Kompozicija
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
PH12014501045B1 (en) 2011-11-09 2019-01-16 Janssen Sciences Ireland Uc Purine derivatives for the treatment of viral infections
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
AU2013261267B2 (en) 2012-05-18 2017-06-29 Sumitomo Pharma Co., Ltd. Carboxylic acid compounds
US20150047463A1 (en) * 2012-06-26 2015-02-19 California Institute Of Technology Systems and methods for implementing bulk metallic glass-based macroscale gears
MX360718B (es) 2012-07-13 2018-11-13 Janssen Sciences Ireland Uc Purinas macrocíclicas para el tratamiento de infecciones víricas.
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014031815A1 (fr) 2012-08-24 2014-02-27 Glaxosmithkline Llc Composés pyrazolopyrimidine
PL2906563T3 (pl) 2012-10-10 2018-10-31 Janssen Sciences Ireland Uc Pochodne pirolo[3,2-d]pirymidyny do leczenia infekcji wirusowych i innych chorób
KR102253773B1 (ko) 2012-11-16 2021-05-20 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 헤테로사이클릭 치환된 2-아미노-퀴나졸린 유도체
RS56233B1 (sr) 2012-11-20 2017-11-30 Glaxosmithkline Llc Nova jedinjenja
WO2014081644A1 (fr) 2012-11-20 2014-05-30 Glaxosmithkline Llc Nouveaux composés
AU2013348216B2 (en) 2012-11-20 2016-10-13 Glaxosmithkline Llc Novel compounds
EP2958900B1 (fr) 2013-02-21 2019-04-10 Janssen Sciences Ireland Unlimited Company Dérivés de 2-aminopyrimidine pour le traitement d'infections virales
JP6336036B2 (ja) * 2013-03-29 2018-06-06 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療のための大環状デアザプリノン
EP3004074B1 (fr) * 2013-05-24 2017-10-25 Janssen Sciences Ireland UC Dérivés de pyridone pour le traitement des infections virales et autres maladies
US9616129B2 (en) 2013-06-22 2017-04-11 Nitor Therapeutics Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
US10385054B2 (en) 2013-06-27 2019-08-20 Janssen Sciences Ireland Unlimited Company Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
DK3027624T3 (en) 2013-07-30 2019-01-07 Janssen Sciences Ireland Uc THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
JP2017503803A (ja) 2014-01-10 2017-02-02 シャンハイ バーディー バイオテック インコーポレイテッド Ｅｇｆｒ発現腫瘍を処置するための化合物及び組成物
MA39898B1 (fr) * 2014-04-22 2020-08-31 Hoffmann La Roche Composés 4-amino-imidazoquinoline
EP3160475B1 (fr) 2014-06-24 2024-01-03 Janssen Pharmaceuticals, Inc. Nucléosides et nucléotides substitués pour traiter les infections dues aux filoviridae
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
AU2015286043B2 (en) 2014-07-09 2020-08-20 Birdie Biopharmaceuticals Inc. Anti-PD-L1 combinations for treating tumors
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
ES2835717T3 (es) 2014-09-16 2021-06-23 Gilead Sciences Inc Formas sólidas de un modulador de receptor de tipo Toll
SG11201704512PA (en) 2014-12-08 2017-07-28 Hoffmann La Roche 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
PE20211647A1 (es) 2015-03-16 2021-08-24 Hoffmann La Roche Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb
CN107743491B (zh) 2015-05-08 2020-08-21 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
EP4001283A1 (fr) 2015-05-12 2022-05-25 F. Hoffmann-La Roche AG Aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale
KR101729236B1 (ko) * 2015-06-01 2017-04-21 (주)노터스생명과학 Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
CN107820498B (zh) 2015-06-30 2020-06-19 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
US10533007B2 (en) 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
CN109071535B (zh) 2016-04-19 2021-10-08 先天肿瘤免疫公司 Nlrp3调节剂
TWI746545B (zh) 2016-04-26 2021-11-21 日商大日本住友製藥股份有限公司 經取代嘌呤衍生物
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
EP3478688A1 (fr) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines pour le traitement d'infections virales
KR20160141683A (ko) 2016-09-21 2016-12-09 (주)노터스생명과학 Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
EP3519406B1 (fr) 2016-09-29 2022-02-23 Janssen Sciences Ireland Unlimited Company Prodrugs des composés de pyrimidine pour le traitement des infections virales et autres maladies
EP3546457B1 (fr) 2016-11-28 2021-07-14 Jiangsu Hengrui Medicine Co., Ltd. Dérivé de pyrazolo-hétéroaryle, son procédé de préparation et son utilisation médicale
MX384745B (es) 2017-01-06 2025-03-14 Hoffmann La Roche Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos.
KR20170010887A (ko) 2017-01-20 2017-02-01 (주)노터스생명과학 Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
WO2018162450A1 (fr) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada Nouvelles compositions immunostimulatrices comprenant une entité protéine de liaison à l'arn inductible à froid (cirp)-antigène pour l'activation des cellules dendritiques
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
EP3636646A4 (fr) * 2017-05-18 2020-12-09 Jiangsu Hengrui Medicine Co., Ltd. Dérivés d'hétéroaryle pyrazole, leur procédé de préparation et leur application médicale
MX2019015744A (es) 2017-06-23 2020-02-20 Birdie Biopharmaceuticals Inc Composiciones farmaceuticas.
WO2019123178A1 (fr) 2017-12-20 2019-06-27 3M Innovative Properties Company Composés imidazo [4,5-c]quinoléine à substitution amide ayant un groupe de liaison à chaîne ramifiée destinés à être utilisés en tant que modificateur de la réponse immunitaire
CN108558864B (zh) * 2018-01-30 2020-07-03 中国医学科学院药用植物研究所 一种瑞喹莫德的酰化衍生物及制备方法与应用
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CA3100873A1 (fr) 2018-05-25 2019-11-28 Jiangsu Hengrui Medicine Co., Ltd. Forme cristalline de chlorhydrate d'un derive pyrazoloheteroaryle et procede de preparation
PE20211598A1 (es) * 2018-05-25 2021-08-18 Primmune Therapeutics Inc Agonistas de tlr7
CN113194945B (zh) * 2018-08-23 2024-07-23 佩勒梅德有限公司 环吡酮的抑制hbv核心组装的用途
EP3846807B1 (fr) * 2018-09-07 2023-08-02 Birdie Biopharmaceuticals, Inc. Composés d'imidazoquinoléine et leurs utilisations
TWI862645B (zh) * 2019-07-27 2024-11-21 美商布里生物科學股份有限公司 腺苷衍生物及包含其之醫藥組合物
IL293293A (en) * 2019-11-26 2022-07-01 Primmune Therapeutics Inc Tlr7 agonists
EP4076445A1 (fr) 2019-12-20 2022-10-26 Nammi Therapeutics, Inc. Compositions liposomales formulées et/ou co-formulées contenant des promédicaments agonistes de récepteurs de type toll (« tlr ») utiles dans le traitement du cancer et méthodes associées
WO2021150613A1 (fr) 2020-01-20 2021-07-29 Incyte Corporation Composés spiro en tant qu'inhibiteurs de kras
JP2023520480A (ja) * 2020-04-02 2023-05-17 サウザーン リサーチ インスチチュート アルファウイルスに対する強力な抗ウイルス剤としての新規２－ピリミドン類似体
WO2021231526A1 (fr) 2020-05-13 2021-11-18 Incyte Corporation Composés de pyrimidine fusionnés utilisés comme inhibiteurs de kras
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022159872A1 (fr) 2021-01-25 2022-07-28 Brii Biosciences, Inc. Dérivé d'adénosine et composition pharmaceutique le comprenant
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
US12077539B2 (en) 2021-03-22 2024-09-03 Incyte Corporation Imidazole and triazole KRAS inhibitors
IL309642A (en) 2021-07-07 2024-02-01 Incyte Corp Tricyclic compounds as inhibitors of Kras
US12441742B2 (en) 2021-08-31 2025-10-14 Incyte Corporation Naphthyridine compounds as inhibitors of KRAS
WO2023049697A1 (fr) 2021-09-21 2023-03-30 Incyte Corporation Composés hétéro-tricycliques utilisés en tant qu'inhibiteurs de kras
EP4408536A1 (fr) 2021-10-01 2024-08-07 Incyte Corporation Inhibiteurs de kras tels que la pyrazoloquinoline
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4539205A (en) 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
GB9015914D0 (en) 1990-07-19 1990-09-05 Wellcome Found Heterocyclic compounds
AU5165793A (en) 1992-10-01 1994-04-26 Mcneilab, Inc. Derivatives of 7,8-disubstituted guanosines
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5994321A (en) 1993-12-20 1999-11-30 Aronex Pharmaceuticals, Inc. Antiviral guanine analogs
JP4667543B2 (ja) 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
ES2290969T3 (es) 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
CA2311742C (fr) 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. Nouveaux composes heterocycliques
JPH11180981A (ja) * 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
EP1465639A4 (fr) * 2001-07-27 2006-05-24 Irx Therapeutics Inc Formulations d'adjuvant pour vaccins antiviraux et antibacteriens et leur procede de fabrication
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
JP4493337B2 (ja) 2001-11-27 2010-06-30 アナディス ファーマシューティカルズ インク ３−β−Ｄ−リボフラノシルチアゾロ［４，５−ｄ］ピリミジンヌクレオシド及びその使用
NZ536123A (en) 2002-05-06 2006-09-29 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists

Also Published As

Publication number Publication date
ES2342069T3 (es) 2010-07-01
TW200526237A (en) 2005-08-16
CA2537450C (fr) 2012-04-17
JP2007504232A (ja) 2007-03-01
WO2005025583A3 (fr) 2005-05-19
WO2005025583A2 (fr) 2005-03-24
BRPI0414045A (pt) 2006-10-24
HK1091410A1 (en) 2007-01-19
ES2342069T4 (es) 2011-01-26
MXPA06002309A (es) 2006-05-19
SG146637A1 (en) 2008-10-30
AU2004271972A1 (en) 2005-03-24
OA13310A (en) 2007-04-13
IL173890A0 (en) 2006-07-05
IL173890A (en) 2012-02-29
US20050054590A1 (en) 2005-03-10
GEP20084545B (en) 2008-11-25
KR20060096415A (ko) 2006-09-11
TWI347189B (en) 2011-08-21
CA2537450A1 (fr) 2005-03-24
US20100256169A1 (en) 2010-10-07
US20090298863A1 (en) 2009-12-03
CR8273A (es) 2009-07-10
NZ545536A (en) 2010-04-30
US8034802B2 (en) 2011-10-11
NO20061183L (no) 2006-06-02
US7576068B2 (en) 2009-08-18
TNSN06076A1 (en) 2007-10-03
US7858637B2 (en) 2010-12-28
EP1667694B1 (fr) 2010-04-28
AU2004271972B2 (en) 2010-06-03
AP2006003542A0 (en) 2006-04-30
DE602004026891D1 (de) 2010-06-10
ATE465742T1 (de) 2010-05-15
US20120028999A1 (en) 2012-02-02
EA200600540A1 (ru) 2006-08-25
US8211863B2 (en) 2012-07-03
ECSP066465A (es) 2006-11-16
EP1667694A2 (fr) 2006-06-14

Similar Documents

Publication Publication Date Title
MA28082A1 (fr) Administration de ligands tlr7 et de leurs prodrogues pour traiter l&#39;infection au virus de l&#39;hepatite c
MA31894B1 (fr) Composes organiques
TNSN07066A1 (fr) Inhibiteurs de l&#39;arn-polymerase, dependant d&#39;arn, du virus de l&#39;hepatite c, et compositions et traitements les utilisant
MA33731B1 (fr) Inhibiteurs du virus de l&#39;hépatite c
MA28102A1 (fr) Formulations pharmaceutiques, methodes et schemas d&#39;administration pour le traitement et la prevention des syndromes coronariens aigus
MA24729A1 (fr) Macrolides nouveaux.
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
TNSN00104A1 (fr) Derives d&#39;isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DK1129093T3 (da) Pyrazolopyrimidinonderivater til behandling af impotens
MA32931B1 (fr) Compositions antimicrobiennes
MA27329A1 (fr) Promedicaments a nucleosides 2&#39; et 3&#39; destines a traiter les infections aux flavivirus
MA26717A1 (fr) Macrolides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
MA27848A1 (fr) Formes posologiques d&#39;azithromycine a effets secondaires reduits.
DE69932733D1 (de) Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene
MA29387B1 (fr) Inhibiteurs de la dipeptidyl peptidase iv
MA33806B1 (fr) Inhibiteurs du virus de l&#39;hepatite c
TNSN99214A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN04168A1 (fr) Derives de thiazole et d&#39;oxazole qui modulent l&#39;activite de ppar
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D&#39;UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
ES2194677T3 (es) Suspensiones de trovafloxacina de administracion por via oral.
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
WO2001010387A3 (fr) Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral
TNSN99111A1 (fr) Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
EP1419129A4 (fr) Utilisation d&#39;acides gras a chaine ramifiee et derives de ces acides gras pour le traitement de la douleur